April 24, 2025

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute

Former Director of NCI, Dr. W. Kimryn Rathmell, renowned for cancer research, appointed CEO of The Ohio State University Comprehensive Cancer Center, promising visionary leadership and a commitment to health equity.

The ASCO Post

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 24, 2025

Large Trial Finds No Stroke Benefit From CEP, Study

A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.

Conexiant

April 24, 2025

FDA Expands Indication for Lu-177 Vipivotide Tetraxetan in mCRPC

The indication for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) was expanded by the FDA to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been t...

The ASCO Post

April 24, 2025

Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer

Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 ...

The ASCO Post

April 24, 2025

Executive Orders and Cancer Care

The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencin...

The ASCO Post

April 24, 2025

SGO’s President-Elect Brings Professional Experience and Passion to Her New Role

Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cance...

The ASCO Post

April 24, 2025

FDA Approves Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

The FDA has approved the PD-L1 inhibitor durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cyste...

The ASCO Post

April 24, 2025

Microplastics: Potential Contributor to Carotid Atherosclerosis?

New research links high levels of micronanoplastics in carotid artery plaque to stroke symptoms, suggesting a potential new target for cardiovascular disease prevention.

Conexiant